Clinical Implication of p53 Mutation in Lung Cancer

Author： Campling Barbara G.   El-Deiry Wafik S.  

Publisher： Humana Press, Inc

ISSN： 1073-6085

Source： Molecular Biotechnology, Vol.24, Iss.2, 2003-06, pp. : 141-156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A structural bioinformatics approach to explore the interactions of P53 and BRCA1 gene products on ovarian and breast cancer

By Parija Satyajeet   Kumar Amit  

International Journal of Bioinformatics Research and Applications, Vol. 7, Iss. 1, 2011-03 ,pp. : 1-14

Inderscience Publishers

Access to resources Recommend Favorite

Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53

By Katkoori VR  

Biotechnic & Histochemistry, Vol. 88, Iss. 1, 2013-01 ,pp. : 38-46

Informa Healthcare

Access to resources Recommend Favorite

Molecular Profiling of Thin-Prep FNA Samples in Assisting Clinical Management of Non-Small-Cell Lung Cancer

By Petriella Daniela   Galetta Domenico   Rubini Vincenza   Savino Eufemia   Paradiso Angelo   Simone Giovanni   Tommasi Stefania  

Molecular Biotechnology, Vol. 54, Iss. 3, 2013-07 ,pp. : 913-919

Humana Press, Inc

Access to resources Recommend Favorite

Gene Therapy for Lung Cancer

By Haura Eric B.   Sotomayor Eduardo   Antonia Scott J.  

Molecular Biotechnology, Vol. 25, Iss. 2, 2003-10 ,pp. : 139-148

Humana Press, Inc

Access to resources Recommend Favorite

Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers

By Xie Zhigang  

Biotechnology Letters, Vol. 33, Iss. 2, 2011-02 ,pp. : 221-228

Springer Publishing Company

Access to resources Recommend Favorite